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Abstract
Background Insulin resistance is intrinsically related to intramyocellular (IMCL) rather than extramyocellular (EMCL)
triglyceride content. Conflicting results have been reported on the ability of insulin sensitizer agents, such as thiazolidinediones,
to modify muscle fat distribution. The aim of this study was to investigate the role of rosiglitazone on muscle fat compartment
distribution in an adult population of obese non-diabetic metabolic syndrome patients.
Patients and methods Fifteen obese, non-diabetic, metabolic syndrome patients were studied by means of proton nuclear
magnetic resonance (1H-NMR) spectroscopy before and after treatment with rosiglitazone 8 mg ⁄ day for 6 months.
Anthropometrical and metabolic variables were assessed.
Results After rosiglitazone, body weight and hip circumference increased [100.9 (91.12–138.7) vs. 107.0 (79.6–142.8) kg and
118 (107–126) vs. 122 (110–131) cm]; while waist–hip ratio (WHR) decreased from 0.93 (0.87–1.00) to 0.89 (0.82–0.97)
(P < 0.001 for all). Additionally, fasting plasma glucose, insulin and homeostatis model assessment of insulin resistance
(HOMA-IR) significantly decreased while adiponectin increased over threefold [9.7 (3.7–17.7) vs. 38.0 (19.3–42.4) lg ⁄ ml]
without any changes in resistin. Finally, the IMCL did not change [267.54 (213.94–297.94) vs. 305.75 (230.80–424.75)
arbitrary units (AU), P = 0.15] while the EMCL increased [275.53 (210.39–436.66) vs. 411.39 (279.92–556.59) AU; P < 0.01]
therefore decreasing the IMCL-to-EMCL (IMCL ⁄ EMCL) ratio [1.07 (0.78–1.23) vs. 0.71 (0.53–0.96); P < 0.01].
Conclusion Rosiglitazone treatment increased body weight and hip circumference and decreased WHR. More importantly,
it decreased the IMCL ⁄ EMCL ratio by increasing the EMCL without any significant change on the IMCL.
Diabet. Med. 27, 23–29 (2010)
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Abbreviations 1H-NMR, proton nuclear magnetic resonance; AMPK, monophosphate-activated protein kinase; AU,
arbitrary units; BMI, body mass index; CRP, C-reactive protein; EMCL, extramyocellular trygliceride content; FPG,
fasting plasma glucose; HDL, high-density lipoprotein; HOMA, homestasis model assessment; IECV, interassay
coefficient of variation; IMCL, intramyocellular trygliceride content; IR, insulin resistance; LDL, low-density
lipoprotein; MS, metabolic syndrome; PAI-1, plasminogen activator inhibitor 1; PPAR-c, peroxisome proliferator-
activated receptor- c; QUICKI, quantitative insulin sensitivity check index; WHR, waist–hip ratio
Introduction
The metabolic syndrome (MS) is considered as a highly prevalent
and important clinical entity related to Type 2 diabetes and
cardiovascular risk [1–5]. Formerly, it was also known as the
insulin resistance syndrome, because of the seminal importance
of insulin resistance (IR) as its main pathophysiological basis. IR
may, however, be a bystander of more complex mechanisms
involving visceral obesity, ectopic fat deposition and
dysfunctional adipose tissue [6]. Liver and muscle fat deposits
are the main sites for IR-related pathophysiology [7].
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Excessive fatty acids could be deposited as triglycerides at the
extramyocellular (EMCL) as well as the intramyocellular
(IMCL) compartments. The IMCL is intrinsically related to IR.
Indeed, several studies utilizing proton nuclear magnetic
resonance (1H-NMR) spectroscopy have confirmed that the
size of the IMCL is the main predictor of IR [8,9].
Adipose tissue is now considered as a dynamic endocrine
organ, producing several proteins (adipokines). Adiponectin,
an adipokine almost exclusively produced by the adipose
tissue, is directly related to insulin sensitivity [10–12] and to
IMCL in obese adolescents [13]. We, as well as other
authors, have recently demonstrated an inverse relationship
between IMCL size, but not EMCL, and adiponectin in
adults [14,15].
Thiazolidinediones, insulin sensitizer agents acting as
peroxisome proliferator-activated receptor- c (PPAR- c)
agonists, may decrease circulating fatty acids and ameliorate
fat distribution, including liver fat reduction [16]. In culture of
muscle cells from diabetic patients it has been demonstrated that
troglitazone, a formerly marketed PPAR- c agonist, increased
fatty acid oxidation [17], potentially reducing intramyocellular
triglycerides. Therefore, a plausible mechanism for its action as
an insulin sensitizer may be through reduction in muscle fat
deposition.Fewstudies inhumanshave lookedat this subject and
their results are conflicting, showing increases in EMCL after
rosiglitazone [18], decreasing levels in IMCL after pioglitazone
and metformin [19] and, finally, decrements in IMCL after
pioglitazone, but not after metformin [20]. It is possible that
some methodological differences may have contributed to
reported results.
Therefore, our aim was to investigate if rosiglitazone, used for
a longer period of time, in a group of non-diabetic, MS patients,
not taking other drugs acting on carbohydrate metabolism,
influences muscle fat distribution.
Patients and methods
Sixteen obese adults [body mass index (BMI) 38.0 
5.7 kg ⁄ m2; aged 41.4  8.7 years; 11 females), MS patients,
defined by the National Cholesterol Education Treatment
Program—Adult Treatment Panel III (NCEP-ATPIII) [21] were
selected at the Cardiometabolic Clinic for outpatient care of the
State University of Rio de Janeiro. Rosiglitazone in a dose of
8 mg daily was administered to all volunteers for a 6-month
period. Initially, the sample size was inferred based on
Mayerson’s study [18], but we have almost doubled their
sample size and extended the follow-up period by an additional
3 months. In order to avoid changes in fat deposition, patients
were advised to maintain their usual diet and lifestyle
throughout the study. Exclusion criteria included diabetes,
smoking and previous cardiovascular, kidney or liver diseases.
Patients taken drugs known to affect glucose or lipid
metabolism were excluded. All subjects gave written
informed consent and the local Ethical Committee approved
the protocol.
Anthropometric measurements and blood pressure
Height, weight, waist and hip circumferences, as well as blood
pressure were collected by the same trained examiner as
previously reported [22]. BMI was defined as the ratio between
weight in kilograms and squared height in meters.
Waist circumferencewasobtainedbymeasuring thenarrowest
pointmidwaybetween the iliac crest and the lowercostal margin.
Hip circumference was measured at the largest diameter of the
gluteal region. Waist–hip ratio (WHR) was determined by
dividing the waist by the hip circumference. Supine blood
pressure was measured twice after a 15-min rest using an
automatic sphygmomanometer (multi-parameter patient
monitor—LifeWindow LW6000; Digicare Biomedical
Technology, West Palm Beach, WA, USA).
Assessment of insulin sensitivity and biochemical analysis
All patients underwent an oral glucose tolerance test using 75 g
anhydrous glucose. Results were used to classify glucose
tolerance state. As stated before, patients with Type 2 diabetes
mellitus were excluded, but those with impaired glucose
tolerance (IGT) were allowed to participate. Blood samples
were collected after a 12-h overnight fast. All laboratory
measurements were performed in duplicate using an automated
method (Modular Analytics PP; Roche, Basel, Switzerland).
Fasting plasma glucose (FPG), total cholesterol, triglycerides and
high-density lipoprotein (HDL) cholesterol were measured
respectively, by enzyme-colourimetric GOD-PAP [interassay
coefficient of variation (IECV) = 1.09%], enzymatic GPO-PAP
(IECV = 2.93%), enzymatic GPO-PAP (IECV = 1.29%) and
enzyme colourimetric without pre-treatment (IECV = 3.23%).
Plasma low-density lipoprotein (LDL) cholesterol was calculated
according to Friedwald equation. Fasting plasma insulin was
measured by automated chemoluminiscence (IECV = 4.68%).
Fibrinogen (IECV = 4.33%) and high-sensitivity C-reactive
protein (CRP) (IECV = 2.66%) were measured respectively by
coagulometric and imunoturbidimetry methods on Modular
Analytics P (Roche). Blood samples were centrifuged and stored
at )70C for further analysis of adipokines. Adiponectin, resistin
and plasminogen activator inhibitor 1 (PAI-1) were measured by
human serum adipokine (panel A, Lincoplex kit CAT, HADK1,
61K-A; Linco Research, St Charles, MO, USA). Intra- and IECVs
were 6.11 and 13.2%, 7.26 and 9.12%, 4.37 and 20.8%,
respectively [22]. Homeostasis model assessment (HOMA) [23]
and the quantitative insulin sensitivity check index (QUICKI)
[24] were calculated to assess insulin resistance.
Assessment of muscle lipids
After an overnight fast, 1H-NMR spectroscopy of the right
soleus muscle was performed using a 1.5T MR Scanner
(Magneton Vision; Siemens, Erlangen, Germany). Subjects
were instructed to avoid strenuous physical exercise for at
least 2 days before the examination. They were positioned
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supine with their right lower leg at the centre of the coil. Thus,
the tibia was oriented nearly parallel to the static magnetic field.
The coil centre was approximately 10–15 cm below the knee
joint. The volume of interest (13 · 13 · 30 mm3) was centred
within the soleus muscle and placed to avoid vascular structures
and gross adipose tissue deposits. Spectra were acquired by
point-resolved spectroscopy (PRESS) sequence with the
following parameters: echo time 135 or 270 ms, repetition
time 1600 ms and 128 or 256 scans with water suppression.
IMCL was calculated from peak areas of IMCL methylene
(CH2) between 1.2 and 1.3 lg ⁄ g. EMCL was calculated from
EMCL methylene between 1.4 and 1.5 lg ⁄ g. The creatine signal
between 2.9 and 3.1 lg ⁄ g served as an internal reference for
IMCL and EMCL quantification.
Statistical analysis
All group data are reported as median (first to third quartiles),
unless otherwise stated, and were analysed by Prism 4.01
(Graphpad Inc., San Diego, CA, USA). The pooled group was
divided into two subgroups, according to quartiles of weight
gain. Comparison r within group at baseline and after treatment
period was performed using Wilcoxon matched-pairs test.
Significant differences were assumed to be present at P < 0.05.
Results
After 6 months, 15 patients ended the treatment period and had
1H-NMR spectroscopy performed. Therefore, data included are
for those who completed the whole study protocol.
Table 1 depicts data for all patients included in the final
analysis. After 6 months of rosiglitazone treatment there was a
significant increase in weight, BMI and hip circumference
without change in waist circumference. Consequently, WHR
decreased after treatment [0.93 (0.87–1.0) vs. 0.89 (0.82–0.97);
P < 0.001].
Changing patterns of muscle triglyceride distribution after
rosiglitazone was our main objective. IMCL did not change but
EMCL significantly increased (Table 1). There was also an
important increase in body weight and the pooled group was
subsequently divided into higher (fourth quartile; i.e. ‡ 4.1 kg)
and lower weight gainers during treatment. Once again, even in
those who gained more than 4.0 kg there was no increase on
IMCL (Fig. 1). In contrast, EMCL significantly increased in both
groups. The IMCL to EMCL (IMCL ⁄ EMCL) ratio was then
calculated in the pooled group at baseline and after treatment.
This ratio significantly decreased after rosiglitazone [1.07 (0.78–
1.23) vs. 0.71 (0.53–0.96); P < 0.01, Fig. 2]. Regarding
glycaemic status, nine patients had impaired glucose tolerance.
All studied variables related to carbohydrate metabolism showed
a consistent modification, where FPG, insulin and HOMA-IR
decreased and QUICKI increased. Adiponectin increased over
threefold above basal level [9.7 (3.7–17.7) vs. 38.0 (19.3–42.4)
lg ⁄ ml; (P < 0.001)], while resistin levels were unchanged
(Table 1). There were small but significant increases in total
and LDL cholesterol, but HDL cholesterol and triglycerides did
not change (Table 1). Finally, a significant  70% reduction in
CRP level was achieved [1.0 (0.5–2.3) to 0.3 (0.2–0.5) mg ⁄ l;
P < 0.0001], while fibrinogen, but not PAI-1, decreased
significantly (Table 1).
Rosiglitazone was well tolerated and only one patient
developed minor pre-tibial oedema. Weight gain was the major
side effect noticed.
Discussion
The main findingof this study was an increase in fat deposition in
the extramyocellular muscle compartment after 6 months of
treatment with an agonist of the PPAR- c, rosiglitazone.
However, this was not observed at the intramyocellular
compartment, where triglyceride content was unchanged.
Therefore, the IMCL ⁄ EMCL ratio significantly decreased
(Fig. 2). It seems that there is a small increase in IMCL after
rosiglitazone. Indeed, the median and third quartiles of IMCL
increased by 14 and 42%, respectively. However, this was far
from being statistically significant. Possiblya larger sample size in
future studies may clarify this point.
Although augmentation of fatty acid disposal in skeletal
muscle from diabetic patients has been demonstrated in vitro
[17], potentially reducing IMCL, clinical studies in humans
have shown contradictory results. Indeed, Mayerson and co-
workers [18] studying diabetic patients taking rosiglitazone for
only 3 months could not demonstrate any improvement in
IMCL. Instead, a 39% increase in EMCL was achieved. Their
results are in accordance with our findings, i.e. a 49.3%
increase in EMCL. In contrast to the present study, there was
no weight gain in Mayerson’s group. Because of the massive
weight gain achieved by our patients, they were divided into
those who gained 4.1 kg or more (fourth quartile of weight
gain) and those who did not. It then became apparent that
IMCL did not change substantially in either group, whilst
EMCL increased, even in those who gained < 4.1 kg. Thus,
there was a significant decrease in the IMCL ⁄ EMCL ratio
(Fig. 2). One study in Zucker fatty rats also showed similar
results, i.e. a decrease in the IMCL ⁄ EMCL ratio with
rosiglitazone [25].
Teranishi and co-workers [19] succeeded in demonstrating
decreased IMCL after pioglitazone or metformin in a group of
Type 2 diabetic patients. In contrast to our study, however,
weight did not increase with pioglitazone and decreased slightly
in the metformin group. This may suggest that lifestyle
modification, including exercises and dietary changes,
implemented before and maintained during the intervention
period, as stated by the authors, influenced their results. Rasouli
and co-workers [20] used muscle biopsy rather than 1H-NMR
spectroscopy in a group of glucose intolerant otherwise healthy
subjects treated with pioglitazone or metformin for 10 weeks.
There was a 34% decrease in IMCL with pioglitazone but no
change within the metformin group. A modest increase in body
weight (2.63  0.65 kg) was accompanied by a decrease in
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Weight (kg) 100.9 (91.12–138.7) 107.0 (79.6–142.8)‡
BMI (kg ⁄ m2) 38.1 (32.8–44.3) 38.4 (34.6–48.4)‡
Waist (cm) 106.0 (98.0–112.0) 109.0 (101.0–114.0)
Hip (cm) 118 (107–126) 122 (110–131)‡
WHR 0.93 (0.87–1.00) 0.89 (0.82–0.97)‡
FPG (mmol ⁄ l) 5.7 (5.3–6.1) 5.2 (4.7–5.6)*
Insulin (pmol ⁄ l) 88 (64–122) 54 (43–77)‡
HOMA-IR 3.30 (2.47–4.37) 2.00 (1.61–3.16)‡
QUICKI 0.320 (0.307–0.333) 0.343 (0.321–0.355)‡
Systolic BP (mmHg) 141 (127.5–170) 134 (128.5–157.5)
Diastolic BP (mmHg) 85 (80–95) 83 (79.5–90)
Total cholesterol (mmol ⁄ l) 4.9 (4.45–6.03) 5.2 (4.91–6.85)†
LDL cholesterol (mmol ⁄ l) 3.0 (2.46–4.22) 3.5 (3.15–4.73)†
HDL cholesterol (mmol ⁄ l) 1.1 (0.96–1.19) 1.1 (0.91–1.25)
Triglycerides (mmol ⁄ l) 2.0 (1.11–2.38) 1.7 (1.34–2.38)
C-reactive protein (mg ⁄ l) 1.0 (0.5–2.3) 0.3 (0.2–0.5)‡
Fibrinogen (mg ⁄ dl) 304 (254.2–364.0) 265 (209.7–296.5)*
Adiponectin (lg ⁄ ml) 9.7 (3.7–17.7) 38.0 (19.3–42.4)‡
PAI-1 (ng ⁄ ml) 23.8 (21.2–28.1) 22.5 (20.6–24.7)
Resistin (ng ⁄ ml) 17.3 (17.2–18.2) 17.1 (16.9–17.8)
EMCL (AU) 276 (210–437) 411 (280–557)†
IMCL (AU) 268 (214–298) 306 (231–425)
*P < 0.05, †P < 0.01, ‡P < 0.001.
AU, arbitrary units; BMI, body mass index; BP, blood pressure; EMCL, extramyocellular trygliceride content; FPG, fasting plasma
glucose; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; IMCL, intramyocellular trygliceride
content; LDL, low-density lipoprotein; PAI-1, plasminogen activator inhibitor 1; QUICKI, quantitative insulin sensitivity check index;
WHR, wasit–hip ratio.
FIGURE 1 Intra- (IMCL) and extramyocellular (EMCL) lipid content at baseline and after 6 months of rosiglitazone treatment (post-treatment) divided
according to weight gain during follow-up. AU, arbitrary units.
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visceral-to-subcutaneous fat ratio. Therefore, differences in
methodology (muscle biopsy), in weight changes, periods of
treatment or even in drug characteristics may explain our
contradictory results.
A few possible interpretations can be raised from the
present findings: (i) the excess fat was shunted to the extramyo-
cellular compartment, which may behave as peripheral
adipocytes accumulating triglycerides under the influence of
thiazolidinediones [18]; (ii) the excess fat eventually driven into
the intramyocellular compartment has been oxidized by PPAR-c
activation [20] or (iii) fat diversion from ectopic lipid depots into
the subcutaneous depot [18,20,26,27]. Moreover, rosiglitazone
therapy increases adipocyte sensitivity to insulin, thus decreasing
peripheral fat lipolysis [18]. In accordance, in our group of
patients, the massive increase in body weight was accompanied
by modification of indirect measures of body fat distribution,
namely an increase in hip circumference and a decrease in WHR.
In animals, adiponectin increases expression of genes involved
in fatty acid transportation and oxidation, such as acyl-CoA
oxidase, CD36 and uncoupled protein [28]. More importantly,
administration of adiponectin (ADP) increased fat oxidation in
muscle, decreased muscle triglycerides and ameliorated insulin
sensitivity [28]. Thiazolidinediones activate adenosine
monophosphate-activated protein kinase (AMPK) and increase
serum concentration of adiponectin, which also activates AMPK
in both muscle and liver [28,29]. The adiponectin level
significantly increased during our study and could be
responsible for increased muscle fat oxidation. However, as the
IMCL did not decrease, such a relationship could not be
demonstrated. Moreover, there was no correlation between the
IMCL ⁄ EMCL ratio decrement and adiponectin increment (data
not shown).
Regarding the modification of the entire profile of metabolic
variables, such as FPG, insulin, HOMA-IR, QUICKI and
fibrinogen, as well as of an inflammatory marker (PCR) and
the lipid profile, this study is entirely in accordance with the
spectrum of action of thiazolidinediones [16]. It is noteworthy
that even in an experimental free living situation, where patients
gained a substantial amount of weight, treatment with
rosiglitazone modified all those markers of insulin sensitivity
towards normal, while ameliorating inflammatory markers. This
may be as a result of favourable fat deposition, as suggested by
the observed increase in body weight and hip circumference
accompanied by decreasing WHR. Accordingly, in Type 2
diabetic patients, rosiglitazone decreases insulin resistance while
increasing leptin, a marker of total body fat. Interestingly, an
increase in maximum subcutaneous fat thickness after
rosiglitazone, measured by sonography, correlated positively
with leptin augmentation and negatively with HOMA-IR [30].
Taken together, amelioration of metabolic parameters may be a
result of decreased IR secondary to peripheral fat deposition.
This study has a number of limitations: ideally, when a drug
intervention is tested, a control, placebo-treated group should be
included. However, in such a group of MS patients this could not
be performed. However, the robust amelioration observed in the
majority of metabolic parameters, adiponectin and CRP, as well
as a remarkable (235%) improvement in endothelial function
previously published in the same group [22], support our
conclusions. Additionally, a before-and-after approach means
that the treated group served as their own control. Finally, our
data should not be generalized beyond the population studied
because of the small sample size, tested by non-parametric
methods. Heterogenity of our sample should be considered only
on glycaemic status. However, our aim was not to investigate
differences according to such subgroups as this would need a
bigger sample size.Wehadnot formally checked foradherence to
our instructions regarding diet or physical activity. However, our
patients gained a huge amount of weight, beyond what could be
expected by rosiglitazone treatment, implying that they did not
diet or exercise significantly. Such observations suggest that an
isocaloric diet could have minimized the weight gain.
This study has also a number of advantages. This is the longest
(6 months) study of those looking at thiazolidinedione
intervention and muscle fat. We investigated a homogeneous
population of obese MS adults, although with differences in
glycaemic status as discussed above. A population of patients not
using drugs that could interfere with glucose or fat metabolism is
an additional advantage.
In conclusion, in a group of obese non-diabetic metabolic
syndrome patients, treatment with rosiglitazone for 6 months
increased body weight but improved several metabolic and
inflammatory markers. The IMCL ⁄ EMCL ratio decreased, as
extramyocellular fat increased without an affect on the
intramyocellular fat compartment.
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